Every Form 4 that Bausch Health Companies Inc (BHC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHC filings page.
Bausch Health Companies Inc. (BHC) reported that Aimee J. Lenar, President, US Pharma, sold 36,827 Common Shares on August 19, 2026 at $7.03 per share in an open‑market transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2026, and Lenar now holds 334,853 Common Shares directly.
Bausch Health Companies Inc. reported that Aimee J. Lenar, President, US Pharma, had 5,260 Common Shares withheld on 2026-07-17 at $4.83 per share to satisfy tax withholding obligations upon vesting of Restricted Share Units. After this tax-withholding disposition, she directly holds 371,680 Common Shares.
Aimee J. Lenar, President, US Pharma of Bausch Health Companies Inc., reported a tax-withholding disposition of 23,395 common shares on July 15, 2026 at $4.89 per share. The issuer withheld these shares to satisfy tax obligations on vested Restricted Share Units, leaving her with 376,940 common shares held directly.
Bausch Health Companies Inc. senior vice president, controller and chief accounting officer Steven Hyosig Lee reported a tax-withholding disposition of 3,125 common shares on July 14, 2026, at $4.75 per share, withheld by the issuer to satisfy tax obligations on vesting of Restricted Share Units. Following this, he directly holds 70,114 common shares.
Bausch Health Companies Inc. director Amy B. Wechsler received an equity-based compensation grant rather than cash for her board service for the quarter ending June 30, 2026. She was awarded 1,394 Restricted Share Units, each representing a contingent right to receive one common share.
The grant is recorded at a reference price of $4.93 per share and is classified as a non-derivative acquisition. Following this award, Wechsler’s direct holdings increased to 314,979 common shares, reinforcing that this is a routine compensation-related transaction rather than an open-market purchase.
Paulson John reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director John Paulson reported an equity-based compensation grant and updated his holdings. He received 12,677 Restricted Share Units, issued in lieu of cash compensation for his service on the board for the quarter ending June 30, 2026, each RSU representing one common share at a reference value of $4.93 per share.
Following this grant, Paulson holds 430,242 common shares directly. The filing also reports 73,255,869 common shares held indirectly by investment funds managed by Paulson Capital Inc., where he may be deemed an indirect beneficial owner, while disclaiming beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director Sandra Leung received an equity compensation grant rather than cash for her board service. She acquired 6,845 common shares on June 30, 2026, valued at $4.93 per share, in the form of Restricted Share Units for the quarter ending June 30, 2026.
Each unit represents a contingent right to receive one common share, and following this grant she directly holds a reported total of 97,070 common shares. This is a routine, compensation-related award rather than an open-market purchase or sale.
WECHSLER AMY B reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Amy B. Wechsler received an award of 45,871 restricted share units (RSUs) of common shares. The RSUs have a grant date value of $250,000, will vest immediately before the company’s next Annual Meeting of Shareholders, and will be settled in common shares. Following this grant, Wechsler directly holds 313,585 common shares.
ROBERTS EIRY reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Eiry Roberts received a compensation-related equity grant. On May 22, 2026, she was awarded 45,871 restricted share units (RSUs), which will be settled in common shares at no purchase price. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the company’s next annual meeting of shareholders, and are intended for non-employee directors. Following this grant, Roberts holds 45,871 common shares directly, showing this is an initial or refreshed equity position rather than an open-market purchase or sale.
POWER ROBERT N reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. reported that director Robert N. Power received an equity grant in the form of restricted share units. He was awarded 45,871 RSUs with a grant date value of $250,000, which will vest immediately before the company’s next Annual Meeting of Shareholders and be settled in common shares. Following this grant, he directly holds 300,594 common shares.
Paulson John reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director John Paulson reported an equity compensation grant rather than an open-market trade. He received an award of 45,871 restricted share units with a grant date value of $250,000, which vest on the date immediately preceding the company’s next annual meeting and will be settled in common shares.
Following this award, Paulson directly holds 417,565 common shares. Investment funds managed by Paulson Capital Inc. directly hold 73,255,869 common shares; Paulson may be deemed an indirect beneficial owner of those fund holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
LEUNG SANDRA reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Sandra Leung received an equity award as part of her board compensation. She was granted 45,871 restricted share units with a grant date value of $250,000, which will vest on the date immediately before the company’s next Annual Meeting of Shareholders and be settled in common shares. Following this award, she beneficially owns 90,225 common shares directly.
Lee Frank D. reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Frank D. Lee received an equity grant in the form of restricted share units. On the grant date, he was awarded 45,871 RSUs with a grant date value of $250,000, at a per-share price of $0.00 as a non-cash compensation award.
The RSUs were granted to non-employee directors on the third business day following their election at the Annual Meeting of Shareholders. They vest on the date immediately preceding the next Annual Meeting of Shareholders and will be settled in common shares. Following this grant, Lee directly owns 95,210 common shares.
KAVANAGH SARAH B reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Sarah B. Kavanagh received an equity grant tied to her board service. She was awarded 45,871 common shares in the form of restricted share units (RSUs) with a grant date value of $250,000, at no cash cost to her.
The RSUs vest on the date immediately preceding the company’s next Annual Meeting of Shareholders and will be settled in common shares. Following this award, Kavanagh directly holds 282,230 common shares, reflecting routine, compensation-related stock-based pay for a non-employee director rather than an open-market purchase or sale.
GOETTLER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Michael Goettler received an equity compensation grant in the form of 45,871 restricted share units (RSUs) with a stated grant date value of $250,000. These RSUs vest immediately before the company’s next Annual Meeting of Shareholders and will be settled in common shares, increasing his direct holdings to 76,020 shares.
Garcia Christian A reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Christian A. Garcia received an award of 45,871 common shares on May 22, 2026, reported as restricted share units granted to non-employee directors. The RSUs have a grant-date value of $250,000 and vest immediately before the company’s next Annual Meeting of Shareholders.
After this equity award, Garcia directly holds 135,578 common shares. The RSUs will be settled in Bausch Health common shares when they vest, increasing his share ownership if he continues to serve through the vesting date.
Bausch Health Companies Inc. director Frank D. Lee reported an open-market sale of common shares. On May 19, 2026, he sold 24,456 common shares at an average price of $5.43 per share. Following this transaction, he directly holds 49,339 common shares.
According to the footnote, the shares were sold in the open market under a Rule 10b5-1 trading plan to fund estimated tax obligations from a previously vested equity award granted to the company’s non-employee directors. The filing shows no derivative positions remaining in this report.
Bausch Health Companies Inc. director Sandra Leung received an equity compensation award in the form of Restricted Share Units for her board service for the quarter ending March 31, 2026. She acquired 5,946 common shares at a deemed price of $5.40 per share, bringing her direct holdings to 44,354 common shares.
Bausch Health Companies Inc. director John Paulson reported an equity compensation grant rather than an open-market trade. He acquired 11,574 common share equivalents at $5.40 per share as Restricted Share Units issued in lieu of cash fees for his board service for the quarter ending March 31, 2026.
After this award, he holds 371,694 common shares directly and has an additional 73,255,869 shares reported as indirectly owned by managed funds. A footnote states these securities are directly owned by the funds, and Paulson disclaims beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director Amy B. Wechsler received an equity-based compensation award for Board service. She acquired 1,273 Restricted Share Units issued in lieu of cash compensation for the quarter ending March 31, 2026, each representing a contingent right to receive one common share. Following this grant, she directly holds 267,714 common shares, including the awarded units.
Bausch Health Companies Inc. executive vice president and CFO Jean-Jacques Charhon reported a tax-related share disposition. On the vesting of Restricted Share Units, 49,060 common shares at $5.93 per share were withheld to cover tax obligations, a non-market transaction. After this withholding, Charhon directly holds 706,478 common shares.
Bausch Health Companies Inc. EVP and General Counsel Seana Carson reported several equity transactions in the company’s common shares. She sold 6,856 shares on March 2, 2026 at $5.78 per share and 4,420 shares on March 3, 2026 at $5.77 per share in open-market sales under a pre-arranged Rule 10b5-1 trading plan. The filing also shows share dispositions used to cover tax withholding on vesting of restricted share units, and a cash settlement of 137,922 previously earned performance share unit awards under the company’s 2014 Omnibus Incentive Plan. After the most recent sale, Carson directly holds 616,761 common shares of Bausch Health.
Bausch Health Companies Inc. director and CEO Thomas Appio reported equity award-related transactions in common shares, no par value. On February 27, 2026 and March 2, 2026, the company withheld 83,093 and 83,705 shares, respectively, to satisfy tax withholding obligations upon vesting of restricted share units.
The filing also records an "other" transaction for 1,137,862 performance share unit awards that will be settled in cash rather than company stock, as approved by the board committee and previously disclosed. Following these transactions, Appio directly held 3,453,236 common shares on March 2, 2026.
LEE STEVEN HYOSIG reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. reported that senior vice president, controller and chief accounting officer Steven Hyosig Lee received an equity grant in the form of restricted share units. He was awarded 45,868 common share RSUs at no purchase price, which will vest in three equal annual installments.
These units vest one-third on each of the first three anniversaries of the grant date, conditional on his continued service. Once vested, each RSU will be settled in one common share of Bausch Health. Following this grant, his directly held common shares total 73,239.
Bausch Health Companies Inc. executive Aimee J. Lenar reported equity compensation changes in company common shares. She received a grant of 157,139 restricted share units at $0.0000 per share on February 25, 2026, increasing her direct holdings to 417,913 shares.
These RSUs vest one-third on each of the first three anniversaries of the grant date, contingent on continued service, and are settled in common shares. On February 26, 2026, 17,578 common shares valued at $6.04 per share were withheld to cover tax obligations upon RSU vesting, leaving her with 400,335 directly held shares.
Bausch Health Companies Inc. executive vice president and general counsel Seana Carson reported several equity transactions in company common shares. Carson received an award of 212,350 restricted share units (RSUs), which will vest in three equal annual installments, with vested RSUs settled in common shares.
To cover tax withholding on a prior RSU vesting, 32,211 common shares were withheld and disposed of at $6.04 per share. Carson also completed an open-market sale of 8,388 common shares at $5.95 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 7, 2025. After these transactions, Carson directly holds 809,258 common shares of Bausch Health.
Bausch Health Companies Inc. EVP and CFO Jean-Jacques Charhon reported equity compensation and related tax withholding in this insider filing. On February 25, 2026, he acquired 276,055 restricted share units (RSUs) for no cash consideration. These RSUs vest one-third on each of the first three anniversaries of the grant date, and vested RSUs are settled in Bausch Health common shares.
On February 26, 2026, 35,977 common shares were disposed of at $6.04 per share to satisfy tax withholding obligations upon RSU vesting, rather than as an open-market sale. After these transactions, Charhon directly held 755,538 common shares of Bausch Health.
Bausch Health Companies Inc. director and Chief Executive Officer Thomas Appio reported two equity compensation transactions involving the company’s common shares.
On February 25, 2026, he acquired 815,425 common shares at $0.00 per share as a grant of restricted share units (RSUs). According to the filing, these RSUs vest in three equal annual installments over three years and are settled in common shares upon vesting.
On February 26, 2026, 116,502 common shares were disposed of in a tax-withholding transaction at $6.04 per share to cover obligations arising from RSU vesting, rather than an open-market sale. Following these transactions, Appio directly owned 3,620,034 common shares.
Bausch Health Companies Inc. reported that Chief Executive Officer and director Thomas Appio acquired 1,137,862 Common Shares at a price of $0 through a grant or award tied to performance-based restricted share units (PSUs). These PSUs were earned on February 9, 2026 after the board committee certified financial performance for the period from January 1, 2023 through December 31, 2025. The units remain subject to a service-based vesting condition through March 2, 2026, after which the earned Common Shares will be delivered. Following this award, Appio beneficially owns 2,921,111 Common Shares directly.
Bausch Health Companies EVP and General Counsel Seana Carson reported an acquisition of 137,922 common shares on February 9, 2026 through a performance-based equity award. These shares relate to performance-based restricted share units originally granted on March 2, 2023.
On February 9, 2026, the Talent and Compensation Committee certified financial performance metrics for the period from January 1, 2023 through December 31, 2025, causing the PSUs to be earned. The units remain subject to service-based vesting through March 2, 2026, after which the company will deliver the earned common shares, bringing Carson’s direct beneficial ownership to 637,507 shares.
Bausch Health Companies Inc. director John Paulson reported equity-based board compensation and his holdings in a Form 4 filing. On 12/31/2025, he acquired 8,992 restricted share units at a price of $0, issued in lieu of cash compensation for his service on the board for the quarter ending December 31, 2025. Each unit represents a contingent right to receive one common share of Bausch Health with no par value.
Following this transaction, Paulson beneficially owned 360,120 common shares directly. In addition, 73,255,869 common shares were reported as indirectly owned through investment funds managed by Paulson Capital Inc., where he is the controlling person. The filing notes that Paulson may be deemed an indirect beneficial owner of these fund-held securities and that he disclaims beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director reported receiving an equity-based compensation award for board service. On December 31, 2025, the director acquired 4,586 restricted share units, each representing a contingent right to receive one common share of the company with no par value. These units were issued in lieu of cash compensation for serving on the board for the quarter ending December 31, 2025. Following this award, the director beneficially owned 38,408 common shares on a direct basis.
Bausch Health Companies Inc. reported that one of its directors received equity compensation for board service for the quarter ending December 31, 2025. The director was granted 989 restricted share units, each representing a contingent right to receive one common share with no par value, issued in lieu of cash compensation. After this grant, the reporting person beneficially owned 266,441 common shares, held directly.
Bausch Health Companies Inc. insider filing reports a large share purchase by a major shareholder’s managed funds. On 11/25/2025, investment funds managed by Paulson & Co. acquired 2,500,000 shares of Bausch Health common stock at $6.25 per share. After this transaction, the funds collectively held 73,255,869 shares, reported as indirectly owned "By Managed Funds." The reporting person is identified as a director and 10% owner, and the filing notes that Paulson & Co. and John Paulson may be deemed indirect beneficial owners through their roles with the funds, while formally disclaiming beneficial ownership beyond any pecuniary interest.
Amendment corrects previously reported insider holdings. This Form 4/A updates an earlier filing to state that John Paulson indirectly beneficially owned 70,755,869 common shares of Bausch Health Companies Inc. as of the 09/30/2025 transaction date. The amendment says the corrected amount matches what was reported on a prior Form 4 filed 08/14/2025 and attributes the holdings to funds managed by Paulson Capital Inc., while the reporting person disclaims direct beneficial ownership except for any pecuniary interest. The filing was signed by an attorney-in-fact on 10/06/2025.
John Paulson, a director of Bausch Health Companies Inc. (BHC), received 9,689 restricted share units on 09/30/2025 as compensation for board service for the quarter ended that date; each unit vests into one common share. After the grant, Mr. Paulson directly beneficially owns 351,128 common shares. In addition, he may be deemed an indirect beneficial owner of 32,791,702 common shares held by investment funds managed by Paulson Capital Inc., although the filing disclaims beneficial ownership except to the extent of any pecuniary interest. The transaction was reported on Form 4 and signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies director Sandra Leung was granted 3,673 restricted share units (RSUs) issued in lieu of cash compensation for her service on the board for the quarter ending September 30, 2025. Each RSU represents a contingent right to receive one common share. After the award, the reporting person beneficially owned 33,822 common shares. The transaction was reported on a Form 4 and executed under transaction code V, with the RSUs recorded at $0 price as issued units rather than an open-market purchase.
Bausch Health Companies Inc. director Amy B. Wechsler received 1,065 restricted share units on 09/30/2025 issued in lieu of cash compensation for board service. Each restricted share unit represents a contingent right to one common share and was reported as having a $0 cash price. After the grant, the reporting person beneficially owned 265,452 common shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.